34. Neurofibromatosis Clinical trials / Disease details
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-003405-26-DK (EUCTR) | 22/02/2018 | 24/04/2017 | Treating learning disabilities in Neurofibromatosis 1 using lamotrigine | The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) - Treating learning disabilities in Neurofibromatosis 1 using lamotrigine | Neurofibromatosis type 1 MedDRA version: 20.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE INN or Proposed INN: lamotrigine Other descriptive name: LAMOTRIGINE | Erasmus MC | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | Spain;Belgium;Denmark;Netherlands | ||
| 2 | EUCTR2016-005022-10-DE (EUCTR) | 13/02/2018 | 09/11/2017 | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Product Name: Lovastatin INN or Proposed INN: Lovastatin Other descriptive name: LOVASTATIN Product Name: Lamotrigin beta INN or Proposed INN: Lamotrigin | Technische Universität München, Fakultät für Medizin | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Germany | ||
| 3 | EUCTR2013-003405-26-ES (EUCTR) | 16/10/2017 | 31/07/2017 | Treating learning disabilities in Neurofibromatosis 1 using lamotrigine | The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) | Neurofibromatosis type 1 MedDRA version: 20.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000012614;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE | Erasmus MC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | Belgium;Spain;Netherlands | ||
| 4 | EUCTR2013-003405-26-BE (EUCTR) | 30/04/2015 | 30/03/2015 | Treating learning disabilities in Neurofibromatosis 1 using lamotrigine | The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) | Neurofibromatosis type 1 MedDRA version: 17.1;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Lamotrigine dispers | Erasmus MC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | Belgium;Netherlands | ||
| 5 | NCT02256124 (ClinicalTrials.gov) | October 2014 | 17/9/2014 | Effect of Lamotrigine on Cognition in NF1 | The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial (NF1-EXCEL) | Neurofibromatosis Type 1 | Drug: Lamotrigine;Drug: Placebo | Erasmus Medical Center | Universitaire Ziekenhuizen Leuven;ZonMw: The Netherlands Organisation for Health Research and Development;Hospital Sant Joan de Deu | Terminated | 12 Years | 18 Years | All | 41 | Phase 2/Phase 3 | Belgium;Netherlands;Spain |
| 6 | EUCTR2013-003405-26-NL (EUCTR) | 03/09/2014 | 20/09/2013 | Treating learning disabilities in Neurofibromatosis 1 using lamotrigine | The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) | Neurofibromatosis type 1 MedDRA version: 17.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Lamotrigine dispers INN or Proposed INN: Lamotrigine Other descriptive name: LAMOTRIGINE INN or Proposed INN: lamotrigine Other descriptive name: LAMOTRIGINE | Erasmus MC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | Netherlands |